<DOC>
	<DOC>NCT02005731</DOC>
	<brief_summary>This is a prospective, pilot study for assessing the safety and efficacy of the treatments performed with Renova (LI-ESWT) on symptomatic ED patients.</brief_summary>
	<brief_title>Low Intensity Extracorporeal Shockwave Therapy for Patients With Erectile Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>Good general health Vasculogenic ED for at least 6 months International Index of Erectile Function 6 (IIEFEF) between 11 to 25 Positive response to PDE5I (able to penetrate on demand, Responders) Negative response to PDE5I (unable to penetrate on demand even with maximum PDE5I dosage,Nonresponders) Stable heterosexual relationship for more than 3 months Psychogenic ED Neurological pathology Hormonal pathology Past radical prostatectomy Recovering from cancer during last 5 years Any unstable medical, psychiatric, spinal cord injury and penile anatomical abnormalities Clinically significant chronic hematological disease Antiandrogens, oral or injectable androgens Radiotherapy in pelvic region</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Low Intensity Shockwave</keyword>
	<keyword>Extracorporeal shockwave therapy</keyword>
	<keyword>Erectile dysfunction</keyword>
</DOC>